Paul Hudson, Sanofi CEO (Sipa USA via AP Images)

Sanofi wants to earn the rep for be­ing the hare in drug R&D. But that darn tor­toise keeps stick­ing its head out

This is an im­por­tant day for Sanofi.

For years now it’s been forced to con­sid­er deep doubts sur­round­ing its abil­i­ty to ex­e­cute in R&D, with a long his­to­ry of slow-foot­ed clin­i­cal ad­vances and a weak in-house pipeline. Its cut­ting-edge in­no­va­tion projects came from Re­gen­eron, which it’s been sep­a­rat­ing from. And to­day, dur­ing R&D day, Sanofi CEO Paul Hud­son as well as R&D chief John Reed hope to leave that all be­hind with a force­ful pre­sen­ta­tion on the phar­ma gi­ant’s new­found nim­ble­ness and ca­pac­i­ty to build an ex­cit­ing late-stage pipeline with sev­er­al top projects in hand.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.